DOCSLIB.ORG

Victory Over Cancer Part Two: Understanding History Building the Future Chapter IV − Why You May Not Have Heard About This Breakthrough Before

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Victory Over Cancer Part Two: Understanding History Building the Future Chapter IV − Why You May Not Have Heard About This Breakthrough Before IV. Why You May Not Have Heard About This Breakthrough Before Victory Over Cancer Part Two: Understanding History Building the Future Chapter IV − Why You May Not Have Heard About This Breakthrough Before What You Will Learn in This Chapter In this chapter, we will share with you the answers to the • In order to comprehend the unspeakable consequences of important question why you may have not heard about all this the ‘business with disease’ it is necessary to analyse the his- before. toric past of these investment interests. You will learn about the ‘laws’ of the pharmaceutical invest- • The chemical/pharmaceutical investment industry was behind ment ‘business with disease’. the two world wars of the 20th Century with the purpose of expanding its global markets and control. You will also learn that: • This book is not primarily targeting specific drugs or drug • The directors of the largest pharmaceutical company at that companies but the very nature of the investment ’business time, BAYER, were sentenced in the 1948 Nuremberg War with disease’. Crimes Tribunal for slavery, genocide and other crimes against humanity. • The ongoing cancer epidemic is the result of a business model that economically benefits from expanding diseases • These investment interests are still active today, trying to – not from delivering health. expand their global markets in disregard of the health and lives of millions of people. • The largest obstacle for the elimination of cancer and other common diseases and real progress in health is the invest- • We, today, have to make a choice: Do we tolerate the contin- ment nature of the pharmaceutical industry. uation of diseases as investment markets – or do we unite to eliminate both of them. • The genocidal dimension of the ‘business with disease’ has been a result of the people of the world not recognising its operating principles for almost a century. Our common goal: Handing over to future generations a world in which cancer is largely unknown! 18 19 Victory Over Cancer Part Two: Understanding History Building the Future Chapter IV − Why You May Not Have Heard About This Breakthrough Before The ‘Laws’ of the Pharmaceutical Industry The pharmaceutical industry is an investment indus- For that reason the pharmaceutical industry is conduct- try driven by profits for its shareholders. Curing dis- ing research and development of new drugs almost 1 eases is secondary to this objective. 8 exclusively with new, synthetic – and patentable – molecules. The marketplace of the pharmaceutical industry is 2 the human body as long as it is sick. Natural therapies, including vitamins and other 9 micronutrients are not patentable, do not yield high Expanding diseases is essential for the growth of the profits and, therefore, are being disregarded by the 3 pharmaceutical industry. pharmaceutical investment business. In order to expand disease markets, pharmaceutical Science-based natural health approaches – effective but 4 drugs are primarily targeting symptoms – while ignor- 10 non-patentable – threaten the economic foundation of ing the cellular root causes of diseases. the pharmaceutical investment business with disease. Prevention, root cause treatment and, above all, the Science-based natural health approaches that can effec- 5 eradication of diseases threatens the very foundation of 11 tively prevent and eliminate the root causes of diseases the pharmaceutical investment business. on one side, and an investment industry based on the continuation and expansion of diseases on the other, are The eradication of diseases on one side, and the incompatible by their very nature and, therefore, cannot 6 expansion of the pharmaceutical investment ‘busi- coexist. ness with disease’ on the other, are fundamentally incompatible. Our generation today has the opportunity and responsi- 12 bility to undertake the eradication of today’s most com- The enormous return on investment, i.e., the prof- mon diseases as its most urgent global goal! 7 itability of the pharmaceutical industry, is based on the royalties from patented synthetic drugs. 20 21 Victory Over Cancer Part Two: Understanding History Building the Future Chapter IV − Why You May Not Have Heard About This Breakthrough Before 5-(4-Benzylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol- -2-one The Huge Royalties From Patented N-(4,6-Dimethyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trif- luoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-N-methyl-methanesul- fonamide 5-(4-tert-Butylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-d- ihydro-indol-2-one ‘Chemo’-Cancer Drugs Drive the Investment 5-[4-((1R,5S,6S)-3-Methanesulfonyl-3-aza-bicyclo[3.1.0]hex-6-ylamino)-5-t- rifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one N-Methyl-N-{3-methyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-triflu- oromethyl-pyrimidin-4-ylamino]-butyl}-methanesulfonamide N-(6-Methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethy- l-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide Business With the Cancer Epidemic 5-{4-[(2-Methanesulfonyl-pyridin-4-ylmethyl)-amino]-5-trifluoromethyl-pyr- imidin-2-ylamino}-1,3-dihydro-indol-2-one 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4- -ylamino]-ethanesulfonic acid amide N-(3-{Methyl-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-- pyrimidin-4yl]-amino}-propyl)-methanesulfonamide N-(2-{Methyl-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-- pyrimidin-4-yl]-amino}-ethyl)-methanesulfonamide 5-[4-(2-Methanesulfonylmethyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-- ylamino]-1,3-dihydro-indol-2-one Patents are the key economic and legal tools of the entire pharma- 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4- -ylamino]-ethanesulfonic acid dimethylamide N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethy- l-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide ceutical business model. They allow the drug companies owning Ethanesulfonic acid methyl-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-py- rimidin-4-ylamino]-methyl}-phenyl)-amide Ethanesulfonic acid (2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- -4-ylamino]-methyl}-phenyl)-amide these patents a monopoly on these drugs and control of global mar- N-Ethyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- -pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide kets. Moreover, by arbitrarily defining the size of the patent royalties, N-{1,1-Dimethyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluorome- thyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide N-(5,6-Dimethyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluorom- ethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-N-methyl-methanesulfonami- de the drug companies became the largest and most profitable corpora- 5-{4-[((R)-4-Methanesulfonyl-morpholin-3-ylmethyl)-amino]-5-trifluorome- thyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one Propane-1-sulfonic acid (2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- -4-ylamino]-methyl}-phenyl)-amide tions in the world. 5-{4-[2-((R)-4-Methanesulfonyl-morpholin-3-yl)-ethylamino]-5-trifluoromet- hyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one Ethanesulfonic acid methyl-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-py- rimidin-4-ylamino]-methyl}-pyridin-2-yl)-amide Trifluoro-N-methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifl- uoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide On these pages we show just one example from the tens of thousands Cyclopropanesulfonic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyr- imidin-4-ylamino]-propyl}-amide N-Ethyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- -pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide of drug patents currently owned by pharmaceutical companies US Ethanesulfonic acid methyl-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trif- luoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide Pat. No. 7,109,337, granted to drug maker Pfizer on September 6, Ethanesulfonic acid ethyl-(2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyri- midin-4-ylamino]-methyl}-phenyl)-amide thanesulfonic acid ethyl-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluorom- ethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide 2006, for anti-cancer chemicals (www.uspto.gov). N-Ethyl-N-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-triflu- oromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide Ethanesulfonic acid (5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-- pyrimidin-4-ylamino]-methyl}-phenyl)-amide Ethanesulfonic acid (3-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-- pyrimidin-4-ylamino]-methyl}-phenyl)-amide These two pages list more than one hundred chemical structures that Ethanesulfonic acid methyl-(3-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoro- methyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4- -ylamino]-ethanesulfonic acid methylamide Pfizer ‘owns’ as its property. Each chemical substance (line) may only Ethanesulfonic acid {3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-- 4-ylamino]-propyl}-amide C-Methanesulfonyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-triflu- oromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide differ by one or a few atoms from the other substances listed.
Load more

Recommended publications
  • Deutsche Peinlichkeiten Zeitgeschichte Die Wirtschaft War an Den Verbrechen Der NS-Zeit Beteiligt, Sie Hat Von Ihnen Profitiert
    Wirtschaft Deutsche Peinlichkeiten Zeitgeschichte Die Wirtschaft war an den Verbrechen der NS-Zeit beteiligt, sie hat von ihnen profitiert. Doch die Unternehmen leugneten diese Schuld – noch Jahrzehnte nach dem Krieg. s war ein fürchterlicher Satz, den Benz 1986 mit dem Thema Zwangsarbeit Tatbestand“. Business as usual. Firmenju - Fritz ter Meer 1948 sagte, in den Ver - konfrontiert. Die Reaktion des Konzerns biläen waren überhaupt willkommene An - Enehmungen der Alliierten. Es war markierte einen unternehmenshistorischen lässe, die Geschichte umzuschreiben. im IG-Farben-Prozess, in dem der deut - Wandel: Statt der üblichen Rechtfertigungs - Als der Edelmetallhersteller Degussa im sche Manager schließlich wegen Verskla - reflexe stellte man sich der Vergangenheit. Jahr 1973 sein 100-Jähriges feierte, wurden vung und Plünderung zu sieben Jahren Der Prozess dieses Eingeständnisses dau - Arisierungen zu Firmenübernahmen um - Haft verurteilt wurde. erte lange, und er liest sich von heute aus gebogen. Das Schädlingsbekämpfungsmit - Ter Meer hatte den Aufbau des IG-Far - wie eine Sammlung historischer Peinlich - tel Zyklon B eines Degussa-Ablegers, das ben-Werks in Auschwitz mitverantwortet, keiten. Noch 1992 blockte etwa Siemens zum industriellen Massenmord in Au - bei dem etwa 30 000 Menschen ums Leben Entschädigungen mit dem Argument ab, schwitz gedient hatte, wurde nicht er - gekommen waren. Seine Verteidigung? der Konzern habe Zwangsarbeiter „nicht wähnt. Stattdessen durfte Festredner Golo Den Zwangsarbeitern sei kein besonderes freiwillig genommen“ und sich an ihnen Mann die Firmengeschichte der Degussa- Leid zugefügt worden, „da man sie ohne - „nicht ungerechtfertigt bereichert“. Kaufleute zu einem Entwicklungsroman dies getötet hätte“. Brünger spricht von „eingängigen Ent - „im Stil der ,Buddenbrooks ‘“ verklären. Fritz ter Meer starb 1967.
    [Show full text]
  • I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz Robert Simon Yavner Old Dominion University
    Old Dominion University ODU Digital Commons History Theses & Dissertations History Summer 1984 I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz Robert Simon Yavner Old Dominion University Follow this and additional works at: https://digitalcommons.odu.edu/history_etds Part of the Economic History Commons, and the European History Commons Recommended Citation Yavner, Robert S.. "I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz" (1984). Master of Arts (MA), thesis, History, Old Dominion University, DOI: 10.25777/7cqx-5d23 https://digitalcommons.odu.edu/history_etds/27 This Thesis is brought to you for free and open access by the History at ODU Digital Commons. It has been accepted for inclusion in History Theses & Dissertations by an authorized administrator of ODU Digital Commons. For more information, please contact [email protected]. 1.6. FARBEN'S PETRO-CHEMICAL PLANT AND CONCENTRATION CAMP AT AUSCHWITZ by Robert Simon Yavner B.A. May 1976, Gardner-Webb College A Thesis Submitted to the Faculty of Old Dominion University in Partial Fulfillment of the Requirements for the Degree of MASTER OF ARTS HISTORY OLD DOMINION UNIVERSITY August 1984 Approved by: )arw±n Bostick (Director) Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Copyright by Robert Simon Yavner 1984 All Rights Reserved Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. ABSTRACT I.G. FARBEN’S PETRO-CHEMICAL PLANT AND CONCENTRATION CAMP AT AUSCHWITZ Robert Simon Yavner Old Dominion University, 1984 Director: Dr. Darwin Bostick This study examines the history of the petro­ chemical plant and concentration camp run by I.G.
    [Show full text]
  • La Sucia Historia De IG Farben
    Startseite home (engl) francais italiano espanol Photo Artículos Fosgeno IG Farben Venezuela Tea Party Bayer USA BAYER Bhopal Bhopal EEUU Institute / USA La sucia historia de IG Farben 6 de diciembre de 2003 La sucia historia de IG Farben Entre 1933 y 1945 la explotación de los obreros alemanes voluntarios, forzados o esclavos y el monopolio químico tenía un nombre: IG Farben. Después de la derrota alemana las potencias victoriosas acabaron con el trust. Así nacieron BASF, Hoechst o Bayer, pero IG Farben siguio existiendo hasta ayer. El pasado 9 de noviembre el antiguo consorcio IG Farben, una especie de INI o SEPI germana, se ha declarado insolvente, pero ese hecho no significa que vaya a desaparecer de forma inmediata: sus acciones siguen siendo objeto de especulación en los corros bursátiles. La historia de la IG Farben se lee como el historial de un criminal. Fundada en 1925 por las mayores empresas alemanas de química, la IG Farben se convirtió en un importante actor en la política alemana de entreguerras. Fue el mayor agente financiero del partido nazi que lideraba Adolf Hitler. Cuando el "Führer" llegó al poder los grandes dirigentes de la IG Farben le aseguraron que habían solucionado el problema de la falta de petróleo: la fabricación de gasolina artificial. Gracias a los ingenieros y técnicos de la IG Farben, Hitler pudo empezar su guerra por el "espacio vital" en Europa. Los estrategas del trust tenían pensando hacerse con los mercados siguiendo a la victoriosa "Wehrmacht". Facilitaron informaciones sensibles al Comando Supremo y colocaron a agentes en sus sucursales.
    [Show full text]
  • The Persistence of Elites and the Legacy of I.G. Farben, A.G
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 5-7-1997 The Persistence of Elites and the Legacy of I.G. Farben, A.G. Robert Arthur Reinert Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the History Commons Let us know how access to this document benefits ou.y Recommended Citation Reinert, Robert Arthur, "The Persistence of Elites and the Legacy of I.G. Farben, A.G." (1997). Dissertations and Theses. Paper 5302. https://doi.org/10.15760/etd.7175 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. THESIS APPROVAL The abstract and thesis of Robert Arthur Reinert for the Master of Arts in History were presented May 7, 1997, and accepted by the thesis committee and department. COMMITTEE APPROVALS: Sean Dobson, Chair ~IReard~n Louis Elteto Representative of the Office of Graduate Studies DEPARTMENT APPROVAL: [)fl Dodds Department of History * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ACCEPTED FOR PORTLAND STATE UNIVERSITY BY THE LIBRARY by on ct</ ~~ /997 ABSTRACT An abstract of the thesis of Robert Arthur Reinert for the Master of Arts in History presented May 7, 1997. Title: The Persistence of Elites and the Legacy of LG. Farben, A.G .. On a massive scale, German business elites linked their professional ambitions to the affairs of the Nazi State. By 1937, the chemical giant, l.G. Farben, became completely "Nazified" and provided Hitler with materials which were essential to conduct war.
    [Show full text]
  • Prominent Nazi Lawyer – and Key Architect of the 'Brussels
    Master Plan of the Nazi/Cartel Coalition – Blueprint for the ‘Brussels EU’ Chapter 2 WALTER HALLSTEIN: Prominent Nazi Lawyer – And Key Architect of the ‘Brussels EU’ Chapter 2 Walter Hallstein (1901-1982) Walter Hallstein was a prominent lawyer involved in the legal and ad- ministrative planning for a post-WWII Europe under the control of the Nazis and their corporate allies, the Oil and Drug Cartel IG Far- ben. Hallstein represented the new breed of members of the Nazi/Cartel Coalition. He was trained by legal teachers whose primary goal was to sabotage the ‘Versailles Treaty’ defining the reparation payments imposed on Germany after it lost WWI. Early on in his career Hall- stein received a special training at the ‘Kaiser Wilhelm Institute in Berlin.’ This private institute was largely financed by the IG•Farben Cartel to raise its scientific and legal cadres for the Cartel’s next at- tempts at the conquest and control of Europe and the world. While the rule of the Nazis ended in 1945, the rule of their accom- plices, the IG Farben Cartel and its successors BAYER, BASF, and HOECHST had just begun. As a strategic part of their plan to launch the third attempt at the conquest of Europe, they placed – a mere decade after their previous attempt had failed – one of their own at the helm of the new cartel ‘politburo’ in Brussels: Walter Hallstein. This chapter documents that the fundamentally undemocratic con- struct of today’s ‘Brussels EU’ is no coincidence. Hallstein, a promi- nent Nazi lawyer – and expert on the IG•Farben concern – was chosen by these corporate interests to become the first EU Commission pres- ident with a specific assignment: to model the ‘Brussels EU’ after the original plans of the Nazi/IG Farben coalition to rule Europe through a ‘Central Cartel Office’.
    [Show full text]
  • PDF Printing 600
    I.G.FARBEN" INDUSTRIE AKTIEN­ GESELLSCHAFT FRANKFURT (J\\AIN) 1 9 4 0 I. G. Farbenindustrie Aktiengesellschaft Frankfurt am Main Bericht des Vorstands und des Aufsichtsrats und Jahresabschluß für das Geschäftsjahr 1940. In Ehrfurcht und Dankbarkeit gedenken wir unserer Kameraden, die ihr Leben im Kampf um die Verteidigung unseres Vaterlandes hingegeben haben. 16. ordentliche Hauptversammlung Freitag, den 8. August 1941, vormittags 11 Uhr, in unseremVerwaltungsgebäude Frankfurt am Main, Grüneburgplatz. Tagesordnung: 1. Vorlage des Jahresabschlusses und des Geschäftsberichts für 1940 mit dem Prüfungs• bericht des Aufsichtsrats und Beschlußfassung über die Gewinnverteilung. 2. Entlastung von Vorstand und Aufsichtsrat. 3. Ermächtigung des Vorstands bis zum 1. August 1946 zur Erhöhung des Grund­ kapitals um bis RM 100000000.- durch Ausgabe neuer Stammaktien gegen Geld­ oder Sacheinlagen (genehmigtes Kapital). Änderung des § 6 der Satzung. 4. Wahlen zum Aufsichtsrat. 5. Wahl des Abschlußprüfers für das Geschäftsjahr 1941. VORSTAND. Geheimer Kommerzienrat Dr. HER M AN N SC H M IT Z, Ludwigshafen a. Rh./Heidelberg, Vorsitzer, Dr. FRITZ GAJEWSKI, Leipzig, Professor Dr. HEINRICH HÖRLEIN, Wuppertal-Elberfeld, Dr. AUGUST v. KNIERIEM, Mannheim, Zentralausschuß Dr. FRITZ TER MEER, Kronberg (Taunus), Dr. CHRISTIAN SCHNEIDER, Leuna, Dr. GEORG von SCHNITZLER, Frankfurt am Main, Dr. OTTO AMBROS, Ludwigshafen a. Rh., Dr. MAX BRÜGGEMANN, Käln-Marienburg, Dr. ERNST BÜRGIN, Bitterfeld, Dr. HEINRICH BÜTEFISCH, Leuna, PAUL HAEFLIGER, Frankfurt am Main, Dr. MAX JLGNER, Berlin-Steglitz, Dr. CONSTANTIN JACOBI, Frankfurt am Main, Dip!. Ing. FRIEDRICH JÄHNE, Frankfurt am Main, Dr. HANS KÜHNE, Leverkusen-LG. Werk, Professor Dr. CARL LUDWIG LAUTENSCHLÄGER, Frankfurt am Main, Generalkonsul WILHELM RUDOLF MANN, Berlin-Grunewald, Dr. HEINRICH OSTER, Berlin-Charlottenburg, Kommerzialrat WILHELM OTTO, Berlin-Zehlendorf-West, Dr.
    [Show full text]
  • Criminales Y Las Actividades Ilícitas Del Régimen Nazi
    Panacea encadenada: La farmacología alemana bajo el yugo de la esvástica Excmo. Sr. Dr. D. Francisco López Muñoz Panacea encadenada: La farmacología alemana bajo el yugo de la esvástica Discurso de ingreso en la Reial Acadèmia de Doctors, como Académico de Número, en el acto de su recepción el 23 de julio de 2015 Excmo. Sr. Dr. D. Francisco López Muñoz Doctor en Medicina y Cirugía Doctor en Lengua Española y Literatura Y contestación del Académico de Número Excmo. Sr. Dr. D. Joan-Francesc Pont Clemente Doctor en Derecho Col·leCCió Reial aCadèmia de doCtoRs Reial Acadèmia de Doctors www.reialacademiadoctors.cat © Francisco López Muñoz © Reial Acadèmia de Doctors. La Reial Acadèmia de Doctors, respetando como criterio de autor las opi- niones expuestas en sus publicaciones, no se hace ni responsable ni solida- ria. Quedan rigurosamente prohibidas, sin la autorización escrita de los titula- res del “Copyright”, bajo las sanciones establecidas en las leyes, la repro- ducción total o parcial de esta obra por cualquier medio o procedimiento, comprendidos la reprografía y el tratamiento informático y la distribución de ejemplares de ella mediante alquiler o préstamos públicos. Producción Gráfica: Ediciones Gráficas Rey, S.L. Impreso en papel offset blanco Superior por la Reial Acadèmia de Doctors. ISBN: 978-84-606-9641-4 Depósito Legal: B 17701-2015 Impreso en España –Printed in Spain- Barcelona Fecha de publicación: julio 2015 ÍNDICE PrEsentacióN y agradecimieNtos ........................................... 9 DIsCurso DE ingrEso ...................................................................... 13 INTRODuCCIóN ..................................................................................... 13 EL DESARROLLO HISTÓRICO DE LA FARMACOLOGÍA EN ALEMANIA ................................................................................................ 19 La Universidad y el nacimiento de la moderna Farmacología ........................... 21 La industria químico-farmacéutica alemana: el imperio I.G.
    [Show full text]
  • Auteur : Luc Vervliet, Ingenieur En Moleculair Bioloog – 21 Juni 2020. 1
    Auteur : Luc Vervliet, ingenieur en moleculair bioloog – 21 juni 2020. 1 . De geschiedenis van het vaccin Louis Pasteur (1) staat bekend om de pionier van de microbiologie en was tijdens zijn leven bekend om zijn vaccin tegen hondsdolheid. Merk op dat hij scheikunde en natuurkunde studeerde en carrière maakte als hoogleraar scheikunde. Van 1861 tot 1862 publiceerde Pasteur zijn werk waarin hij de theorie van spontane generatie weerlegde (2). Spontane generatie is een aristotelisch begrip dat in onbruik is geraakt (verouderd), uitgaande van de opkomst zonder ascendant, van levende wezens uit levenloze materie. Dit idee houdt verband met het moderne concept van abiogenese (3). Abiogenese is het verschijnen van leven uit levenloze materie. Het concept van abiogenese is in strijd met de theorieën van panspermie (volgens welke de oorsprong van het leven op aarde afkomstig is van buitenaardse inseminatie) (4). In haar moderne conceptie gaat het over het verschijnen van primitieve micro-organismen en (vandaag zeker verdwenen) uit reeds bestaande organische materie en van abiotische oorsprong (= zonder de aanwezigheid van leven) (5). Abiotische stress is stress die het gevolg is van puur fysisch-chemische veranderingen in de omgeving (stikstofgebrek, uitdroging), d.w.z. de extractie van water met chemische of fysische middelen, UV- straling, osmotische druk (6), enz., in tegenstelling tot biotische stress die de schadelijke werking is van het ene levende organisme op het andere (aanval door een infectieus agens bij voorbeeld). Besmettelijke agentia zijn voornamelijk micro-organismen, inclusief bacteriën en virussen (7). Volgens de officiële versie is een virus een besmettelijk agens die een gastheer nodig heeft, vaak een cel, waarvan het metabolisme en de bestanddelen ervan worden gerepliceerd.
    [Show full text]
  • Antony C. Sutton – Wall Street and the Rise of Hitler
    PREFACE This is the third and final volume of a trilogy describing the role of the American corporate socialists, otherwise known as the Wall Street financial elite or the Eastern Liberal Establishment, in three significant twentieth-century historical events: the 1917 Lenin- Trotsky Revolution in Russia, the 1933 election of Franklin D. Roosevelt in the United States, and the 1933 seizure of power by Adolf Hitler in Germany. Each of these events introduced some variant of socialism into a major country — i.e., Bolshevik socialism in Russia, New Deal socialism in the United States, and National socialism in Germany. Contemporary academic histories, with perhaps the sole exception of Carroll Quigley's Tragedy And Hope, ignore this evidence. On the other hand, it is understandable that universities and research organizations, dependent on financial aid from foundations that are controlled by this same New York financial elite, would hardly want to support and to publish research on these aspects of international politics. The bravest of trustees is unlikely to bite the hand that feeds his organization. It is also eminently clear from the evidence in this trilogy that "public-spirited businessmen" do not journey to Washington as lobbyists and administrators in order to serve the United States. They are in Washington to serve their own profit-maximizing interests. Their purpose is not to further a competitive, free-market economy, but to manipulate a politicized regime, call it what you will, to their own advantage. It is business manipulation of Hitler's accession to power in March 1933 that is the topic of Wall Street and the Rise of Hitler.
    [Show full text]
  • DIE MANAGER DER NAZIS Wohl Kalkuliert Und Bereitwillig Hat Sich Die Deutsche Großwirtschaft in Hitlers Militärisch-Industriellen Komplex Eingefügt
    DIE MANAGER DER NAZIS Wohl kalkuliert und bereitwillig hat sich die deutsche Großwirtschaft in Hitlers militärisch-industriellen Komplex eingefügt. Der I. G.-Farben-Konzern wurde aktiver Teil der Kriegsmaschine – er baute sogar ein eigenes KZ: in Auschwitz-Monowitz / VON NORBERT FREI n der Frankfurter Konzernzentrale herrschte Unzufriedenheit. Vor ein paar IMonaten erst hatte das Unternehmen ein übereiltes politisches Engagement mit einer millionenschweren Bauruine bezahlt. Der „Gedanke eines wirtschaftlichen Aufschlus- ses des Ostraumes“, dem die I. G. Farben gern und gierig gefolgt waren, hatte sich als Flop erwiesen. Nun, so wollte es die Politik, sollte sich die Sünde wider Wettbewerb und Weltmarktpreise wiederholen – gegen alle ökonomische Vernunft und offenkundig vor dem Hintergrund riskanter Pläne. Im Spätherbst 1940 rangen die Manager der I. G. Farben, wieder einmal, mit den Spitzen des Dritten Reiches. Ein Jahr zuvor, in der Aufbruchstimmung nach dem „Po- lenfeldzug“, als das eroberte Territorium nur darauf zu warten schien, den „neuen großen fabrikatorischen Stützpunkt für die I. G.“ abzugeben, hatte man sich auf den Bau einer Anlage für synthetischen DIE GEGENWART DER VERGANGENHEIT DER GEGENWART DIE Kautschuk im grenznahen Rattwitz bei Breslau verständigt; das Werk sollte die Pro- MUSEUM AUSCHWITZ duktion in Schkopau und Hüls ergänzen. Buna-Werke in Auschwitz: Zur Arbeit oder direkt ins Gas Doch dann war auch Frankreich gefallen wie im Spiel, und die nationalsozialistische drastischen Eingriffen in die private Unter- rer Gesamtheit seit 1933 eingegangen war. Nachkriegszukunft verhieß ein deutsches nehmerwirtschaft nicht zurückschreckte. Dabei gab es zunächst deutliche Unter- Kolonialreich mit unbegrenztem Zugriff auf Statt es zur Kraftprobe oder gar zum of- schiede. Anders als etwa bei den deutsch- billigen Naturkautschuk.
    [Show full text]
  • CARL KRAUCH Et Al DISSENTING
    MILITARY TRIBUNAL NO. VI CASE NO. 6 THE UNITED STATES OF AMERICA -against- CARL KRAUCH et al DISSENTING OPINION By JUDGE PAUL M. HEBERT on COUNT THREE OF THE INDICTMENT UNITED STATES MILITARY TRIBUNAL VI P ALACE OF JUSTICE, BURNBERG, GERMANY Case No. 6 THE UNITED STATES OF AMARICA -vs- CARL KRAUCH, HERMANN SCHMITZ, GEORG VIN SCHNITZLER, FRITZ GAJEWSKI, HEINRICH HOERLEIN, AUGUST VON KNIERIEM, FRITZ TER MEER, CHRISTIAN SCHNEIDER, OTTO AMBROS, ERNST BUERGIN, HEINRICH BUETEFISCH, PAUL HAEFLIGER, MAX ILGNER, FRIEDRICH JAEHNE, HANS KUEHNE, CARL LAUTENSCHLAEGER, WILHELM MANN, HEINRICH OSTER, KARL WURSTER, WALTER DUERRFELD, HEINRICH GATTINEU, ERICH VON DER HEYDE, AND HANS KUGLER, officials of I.G. FARBENINDUSTRIE AKTIENGESELLSCHAFT Defendants DISSENTING OPINION Count Three of the Indictment This dissenting opinion is filed pursuant to reservations made at the time of the rendition of the final judgment by Military Tribunal VI in this case. Under Count Three of the indictment, all defendants are charged with having committed War Crimes and Crimes Against Humanity as defined in Article II of Control Council Law No. 10. It is alleged in the indictment that the defendants participated in the enslavement and deportation to slave labor on a gigantic scale of members of the civilian population of countries and territories under the belligerent occupation of, or otherwise controlled by Germany; that the defendants participated in the enslavement of concentration camp inmates, including German nationals; that the defendants participated in the use of prisoners of war in war operations and work having a direct relation to war operations, including the manufacture and transportation or war material and equipment; and, that the defendants participated in the mis-treatment, terrorization, torture, and murder of enslaved persons.
    [Show full text]
  • Eu Facts the Information and Documents That Mark the Beginning of the End for the “Brussels Eu” Experiment
    EU FACTS THE INFORMATION AND DOCUMENTS THAT MARK THE BEGINNING OF THE END FOR THE “BRUSSELS EU” EXPERIMENT The Dark Roots of the “Brussels EU” This article highlights the birth place of the "Brussels EU" on the drawing boards of the Nazi/IG Farben-coalition for a post-war Europe under their control. It is an excerpt of the speech by Dr. Rath on the occasion of receiving the "Relay of Life" award from survivors of the Auschwitz concentration camp. The corporate preparations for World War II started as early as 1925, when Bayer, BASF, Hoechst and other German multinationals formed a cartel called “IG Farben Industry”. The declared goal of this cartel was to obtain control of the global markets in the key industrial sectors of chemistry, pharmaceuticals and petrochemicals. Already in 1925, when this cartel was founded, its corporate value surpassed 11 billion Reichsmark and it employed more than 80,000 people. One of the strategic industries for which IG Farben sought global control was the pharmaceutical “investment business”. They knew that the pharmaceutical industry is not primarily a health industry, but an investment business that defines the human body as its marketplace. While presenting itself as the purveyor of health, the entire existence of this investment industry has been based on the continuation and expansion of diseases as multibillion dollar markets for patented drugs. The precondition for establishing a global monopoly for this investment business with patented drugs was the attempt to systematically eliminate all non-patentable natural therapies. In 1933 IG Farben became the largest financier of the Nazis rise to power.
    [Show full text]